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Abstract
Pain is a major symptom of many medical conditions and the worldwide number one reason for people to seek medical
assistance. It affects the quality of life of patients and poses a heavy financial burden on society with high costs of treatment
and lost productivity. Furthermore, the treatment of chronic pain presents a big challenge as pain therapeutics often lack
efficacy and exhibit minimal safety profiles. The latter can be largely attributed to the fact that current therapies target
molecules with key physiological functions throughout the body. In light of these difficulties, the identification of proteins
specifically involved in chronic pain states is of paramount importance for designing selective interventions. Several profiling
efforts have been employed with the aim to dissect the molecular underpinnings of chronic pain, both on the level of the
transcriptome and proteome. However, generated results are often inconsistent and non-overlapping, which is largely due to
inherent technical constraints. A potential solution may be offered by emerging strategies capable of performing standardized
and reproducible proteome analysis, such as data-independent acquisition-mass spectrometry (DIA-MS). We have recently
demonstrated the applicability of DIA-MS to interrogate chronic pain-related proteome alterations in mice. Based on our
results, we aim to provide an overview on DIA-MS and its potential to contribute to the comprehensive characterization of
molecular signatures underlying pain pathologies.
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Overview of current profiling approaches in
pain research
While acute pain is an evolutionary adaptive response,
chronic pain is considered a pathology of the nervous
system. In vertebrates, a painful stimulus is detected by
specialized peripheral sensory neurons like those of dorsal
root ganglia (DRG). These DRG neurons serve as pri-
mary cellular detectors of noxious stimuli.1 Their activity
ultimately shapes the afferent message transmitted via the
spinal cord to different regions of the central nervous
system where the sensation of pain is generated. From a
molecular point of view, the function of each relay station
of this pain axis relies on dedicated protein machineries
that are fine-tuned and highly regulated.1–3
During the past decade, enormous efforts have been
made towards the identification and characterization of
key molecular pathways that orchestrate processes
underlying chronic pain. Excellent previous studies docu-
mented pain-related transcriptome variations using
microarrays and deep sequencing methods (RNA-
Seq).4,5 Although these findings yielded important
insights, the extent to which mRNA alterations account
for protein variability is limited.6 It is thus desirable to
directly assess chronic pain-induced proteome changes,
as the proteome represents the composite readout of
gene expression, translation, and posttranslational
modulation.6 Many investigators have employed MS in
order to reveal proteome changes in tissues from both,
rodent models7–12 and patients suffering from chronic
pain.13,14 Despite the body of knowledge on potentially
regulated proteins generated by these studies, the
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sparsity of overlapping identifications, even for the same
experimental model, is striking.
A common factor of these proteome profiling schemes
is the use of so-called data-dependent acquisition MS
(DDA; commonly referred to as shotgun MS). When a
sample (a mixture of diverse peptides) enters the mass
spectrometer in an average DDA experiment, the most
abundant peptides (i.e., the most intense signals) are
selected for subsequent fragmentation and identification,
while the rest of the peptides are excluded from ana-
lysis.15 This results in ‘‘under-sampling,’’ with the aver-
age DDA-MS experiment identifying only 10% to 20%
of peptides of a given sample.15–17 Furthermore, the
selection of low- and medium-abundant peptides is
very variable, leading to limited reproducibility of detec-
tion between technical replicates (40% to 70%)15— a
relevant problem, especially in complex samples such
as tissue lysates. Consequently, this ambiguity and bias
towards detection of the most abundant proteins,15
paired with differences in sample preparation, are
major obstacles in the quest to monitor the dynamics
of cellular protein networks across different pain states
in a comprehensive and reproducible manner.
Emerging DIA-MS-based proteomics
In the past years, MS has significantly advanced in the
search of novel solutions to circumvent these commonly
encountered problems of classical DDA experiments.
Highly optimized and extended DDA profiling has
successfully achieved extensive proteome coverage.18
Still, limitations hinder its broad implementation in the
pain research community: on one hand, the need of long
instrument times and on the other hand, the lack of tools
that can be shared to standardize the detection of these
large sets of proteins.
One emerging group of MS strategies that have the
potential to overcome these bottlenecks is so-called
data-independent acquisition (DIA)-MS.19–21 DIA-MS
is not only capable of detecting and fragmenting the
majority of peptides present in a complex sample,19–21
but it also does so with high reproducibility enabling
standardization among laboratories. In contrast to
DDA-MS, DIA-MS performs concurrent selection and
fragmentation of nearly all peptides entering the mass
spectrometer on the basis of their mass/charge (m/z)
ratio and irrespective of their intensity (as long as their
intensity is above the detection limit of the mass spec-
trometer). The measured fragmentation data (composed
of retention time, intensity, and m/z data from each frag-
mented ion) for each generated spectrum are stored in
DIA digital maps, which are unique for a given
sample.19–21 However, such digital maps are highly com-
plex as each generated spectrum contains information
from different peptides (referred to as a chimeric
spectrum); this prevents the use of conventional database
search tools to identify unique peptides. Hence, reference
spectral libraries are employed to query these DIA digital
maps in a targeted way.22 A reference spectral library is
built from several highly optimized DDA-MS runs on the
sample of interest in order to achieve the most extended
number of peptide identifications possible.23,24 This com-
pendium of peptides contains the necessary physicochem-
ical information to uniquely identify them in the
aforementioned chimeric spectra of DIA digital maps,
which are produced by subsequent analysis of the same
sample in DIA-MSmode. The use of these reference spec-
tral libraries permits the quantification of thousands of
proteins across different samples with unprecedented
reproducibility.19–21 Another interesting feature of DIA-
MS is that DIA digital maps can be queried in silico any
time using new/extended spectral libraries thereby open-
ing the opportunity to test novel hypotheses without the
need to perform laborious new experiments. These char-
acteristics, together with the availability of both DIA
digital maps and reference spectral libraries in growing
public repositories (PeptideAtlas, http://www.peptidea-
tlas.org), positions DIA-MS as a promising tool towards
highly reproducible and standardized protein profiling.21
Indeed, several reports highlighted the potential of DIA-
MS to interrogate pathology-related proteomes, such as
signatures for tumor characteristics25,26 or drug-related
protein–protein interactions.23,27
DIA-MS-based proteomics in pain research
We have recently demonstrated the applicability of
DIA-MS to pain research and its potential to reach
standardization in future pain-related profiling pro-
jects.28 In our study, we defined and compared changes
in the membrane-enriched proteome of DRG in two
commonly used mouse models of chronic pain with dif-
ferent etiology: inflammatory pain induced by injection
of Complete Freund’s Adjuvant (CFA; Vehicle injections
served as controls) and neuropathic pain using the
spared nerve injury (SNI) model (control groups received
sham surgery). A methodological outline of our work-
flow and experimental design is shown in Figure 1. After
biochemical preparation of the samples, we first gener-
ated a DRG-specific spectral library including samples
from each condition (CFA vs. Vehicle and SNI vs.
Sham). The final spectral library contains information
on 3,067 proteins exhibiting diverse molecular functions
across many cellular compartments as assessed by gene
ontology analysis.28 This spectral library provides the
first available resource of its kind for future DIA-MS
experiments in any tissue such as regions of the pain
axis (the spectral library is deposited in PeptideAtlas;
http://www.peptideatlas.org, No. PASS00826, username:
PASS00826, password: ZE5945at).
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We applied this spectral library for the targeted search
of DIA digital maps obtained from DRG after induction
of inflammatory and neuropathic pain as well as respect-
ive controls (CFA vs. Vehicle and SNI vs. Sham). As a
result, we obtained a quantitative comparison of 2526
proteins across all biological replicates of the four con-
ditions tested. Interestingly, these experiments revealed
significant and largely pain model-specific alterations of
129 proteins, among which are targets that have either
previously been reported to be relevant for nociception
or represent yet uncharacterized proteins. In addition,
the high statistical power of our DIA-MS results allowed
us to uncover global alterations in diverse cellular
protein networks, such as protein maturation and mito-
chondrial function. A comparison with known biology,
combined with our functional validation experiments
using independent animal cohorts, demonstrates that
DRG protein networks relevant for pain and somatosen-
sory signaling were indeed identified.
DRG constitute a major peripheral part of the pain
axis. Yet, pain is perceived and strongly modulated by an
intricate interplay of many regions of the central nervous
system along the pain axis. Elegant studies have docu-
mented prominent pain-induced plasticity in the dorsal
horn of the spinal cord29–32 as well as in diverse suprasp-
inal sites. For example, several forms of synaptic plasti-
city in the anterior cingulate cortex are implicated in
emotional-aversive aspects of pain including pain-related
anxiety.33,34 Moreover, distinct pain-associated
modifications in neuronal activity were found in the pre-
frontal cortex35 as well as in the amygdala.36,37
It is this complexity underlying pain perception and
modulation that renders the search for molecular signa-
tures of pain a challenging endeavor. Nonetheless, the
features offered by DIA-MS towards the standardization
of protein profiling provide novel opportunities. These
include the generation of tissue-specific spectral libraries
and the applicability of existing spectral libraries to
explore proteome changes in any region of the pain axis.
Conclusions and outlook
In spite of its likely impact on molecular pain research,
several limitations, which are currently preventing DIA-
MS from reaching its full potential have yet to be solved.
DIA digital maps are very complex and reliable extrac-
tion of protein information with spectral libraries is
demanding. In our study, for example, the spectral library
(and thus our DIA-MS results) did not contain informa-
tion on many ion channels known to be involved in noci-
ception and pain such as Nav1.7. The reasons can be
manifold, ranging from relative low expression levels
(and consequently difficulties in detection by DDA-MS
used for spectral library generation) to insufficient solubil-
ization—factors known to rendermembrane protein ana-
lysis challenging.38 Hence, optimization of biochemical
sample preparation and spectral library generation will
be key to obtain the most complete coverage of the
Figure 1. Schematic representation of an experimental workflow suitable for standardized and comparative protein profiling in any tissue
of interest across mouse models of chronic pain.
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proteome. In addition, recent advances in both targeted
(using spectral library information22) and untargeted
approaches (using computational workflows39) offer
improved strategies to extract information fromDIAdigi-
tal maps. Moreover, novel MS acquisition strategies40 are
designed to reduce the complexity of DIA maps and to
simultaneously maximize the amount of protein informa-
tion obtained. Further, while to date DDA-MS units are
available in many research institutions, DIA-MS plat-
forms are still in a nascent stage. We expect that the grow-
ing landscape of technological solutions together with the
access to user-friendly DIA analysis software (e.g.,
Skyline, OpenSWATH) will facilitate the incorporation
of DIA-MS into the researchers’ toolbox.
Despite the vast amount of research, pain manage-
ment still relies on the ‘‘one drug fits all’’ model.
However, cellular signaling is diverse and it has long
been known that the function of a single protein may
be modulated by its assembly into dynamic multi-protein
complexes and networks—a fact represented by the con-
cept of cellular ‘‘molecular machines.’’41 Therefore, evol-
ving strategies aimed at correcting dysfunctional
networks may provide promising tools for achieving
analgesia.42 Identifying the composition of such networks
in a tissue-specific manner can greatly facilitate insights
into functional misalignments of pathology-associated
processes with the opportunity to modify them at distinct,
critical hubs.43 This may provide major benefits: (i)
increase of specificity, (ii) possibilities for discrete
tuning of cellular functions, and consequently, (iii) less
side effects on key physiological functions.
The results from our study serve as a proof-of-princi-
ple for the generation of molecular portraits of signaling
networks underlying specific chronic pain states. The
availability of large and tissue-specific spectral libraries
will open the possibility to perform longitudinal studies
investigating the molecular plasticity along the whole
pain axis or even in any tissue of interest. On the clinical
front, DIA-MS has the potential to expedite the long-
awaited stratification of chronic pain conditions through
sensitive and specific diagnostics tools using minimally
invasive liquid biopsy matrices (e.g., plasma).
Consequently, more efficacious and personalized pain
therapies may be developed.
We are confident that forthcoming DIA-MS-based
research efforts of the pain-community will help to initi-
ate new turns on the path towards pain relief.
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